Evaluation of relapse-free survival in T3N0 Colon cancer: The role of chemotherapy, a multicentric retrospective analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Grande, Roberta ^a   Corsi, Domenico ^b   Mancini, Raffaello ^c   Gemma, Donatello ^a   Ciancola, Fabrizio ^a   Sperduti, Isabella ^c   Rossi, Lorena ^b   Fabbri, Agnese ^d   Diodoro, Maria G ^c   Ruggeri, Enzo ^d   Zampa, Germano ^e   Bianchetti, Sara ^f   Gamucci, Teresa ^a  

^a Medical Oncology Unit ASL Frosinone   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d BELCOLLE HOSPITAL   (Italy)

^e ASL RMA   (Italy)

^f Medical Oncology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; CLINICAL TRIAL; COLONIC NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; RECURRENT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84891917203     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080188     Document Type: Article

References (38)

1. Jonker DJ, Spithoff K, Maroun J (2011) Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer after Complete Resection: An Updated Practice Guideline. Clinical Oncology 23(5):314-322.
2. Sato H, Maeda K, Sugihara K, Mochizuki H, Kotake K, et al. (2011) High-Risk Stage II Colon Cancer After Curative Resection. Journal of Surgical Oncology. doi: 10.1002/jso.21914.
3. Stocchi L, Fazio VW, Lavery I, Hammel J (2011) Individual surgeon, pathologist and other factors affecting lymph node harvest in stage II colon carcinoma. Is a minimum of 12 examined lymph nodes sufficient? Ann Surg oncol 18:405-12.
4. NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-50.
5. Otchy D, Hyman NH, Simmang C, Anthony T, Buie WD, et al. (2004) Practice parameters for colon cancer. Dis Colon rectum; 47:1269-84. (Pubitemid 39180201)
6. National Comprehensive Cancer Network guidelines (2012) version 3. Available: http://www.nccn.org. Accessed 2012 Sept.
7. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, et al. (2000) Prognostic factors in colorectal cancer. College of American Pathologist Consensus Statement 1999. Arch Pathol Lab Med 124:979-994. (Pubitemid 30602039)
8. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, et al. (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419. (Pubitemid 41103700)
9. QUASAR Collaborative Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 370:2020-2029.
10. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo L, et al. (2007) Oxaliplatin combined with weekly bolus fliorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSAB P C-07. J Clin Oncol 25:2198-2204. (Pubitemid 46954643)
11. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, et al. (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116.
12. Gertler R, Rosenberg R, Schuster T, Friess H (2009) Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy. Eur J Cancer 45:2992-2999.
13. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol 22(16):3395-3407. (Pubitemid 41103699)
14. Figueredo A, Coombes ME, Mukherjee S (2008) Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. Jul. 16(3):CD005390.
15. Quah HM, Chou JF, Gonen M, Jinru S, Schrag D, et al. (2008) Identification of patients with high risk stage II colon cancer for adjuvant chemotherapy. Dis Colon Rectum 51:503-507.
16. Sarli L, Bader G, Iusco D, Salvemini C, Di Mauro D, et al. (2005) Number of lymph nodes examined and prognosis of TNM stage II colon cancer. Eur J Cancer 41:272-279. (Pubitemid 40126960)
17. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257. (Pubitemid 36859476)
18. Sargent DJ, Marsoni S, Monges J, Thibodeau SN, Labianca R, et al. (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226.
19. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB, et al. (2002) Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol 19:3999-4005.
20. O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou J, et al. (2011) Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features. J Clin Oncol 29:3381-3388.
21. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356-1363.
22. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, et al. (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806. (Pubitemid 41095169)
23. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, et al. (2009) Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 27:872-877.
24. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, et al. (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912-2919. (Pubitemid 46621841)
25. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long T, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787-793. (Pubitemid 43980599)
26. Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369-373.
27. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, et al. (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25:767-772. (Pubitemid 350002875)
28. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, et al. (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology 23:2479-2516. doi:10.1093/annonc/mds236.
29. Sinicrope FA, Sargent DJ (2012) "Molecular Pathways: Microsatellite Instability in Colorectal. Cancer: Prognostic, Predictive, and Therapeutic Implications." Clinical Cancer Res 18 (6). doi:10.1158/1078-0432. CCR-11-1469.
30. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, et al. (2008) Colon Cancer Family Registry Investigators. Molecular characterization of MSI-H colorectal cancer by MLHI promoter meth-ylation, immunohistochemistry, and mismatch repair germline muta-tion screening. Cancer Epidemiol Biomarkers Prev 17:3208-3215.
31. Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, et al. (2011) Documenting the Natural History of Patients with Resected Stage II Adenocarcinoma of the Colon after Random Assignment to Adjuvant Treatment with Edrecolomab or Observation: Results From CALGB 9581. JCO 29:3146-3152.
32. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, et al. (2012) Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. J Natl Cancer Inst. 104(21):1635-1646. doi: 10.1093/jnci/djs427.
33. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, et al. (2011) Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. JCO 29:1261-1270.
34. Salazar R, Roepman P, Capella G, Moreno V, Simon I, et al. (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29:17-24.
35. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, et al. (2011) Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29:4611-4619.
36. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA (2007) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99(6):433-441. (Pubitemid 47073566)
37. Laubert T, Habermann JK, Hemmelmann C, Kleemann M, Oevermann E, et al. (2012) Metachronous metastasis- and survival-analysis show prognostic importance of lymphadenectomy for colon carcinomas. BMC Gastroenterology 12:24. Available: http://www.biomedcentral.com/1471-230X/12/24. Accessed 2013 Nov. 14.
38. Santos C, López-Doriga A, Navarro M, Mateo J, Biondo S, et al. (2012) Clinicopathological risk factors of stage II colon cancer: results of a prospective study. Colorectal Dis. doi: 1111/codi.12028.